NCT00003453 - Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 21, 1996

Primary Completion Date

July 5, 2011

Study Completion Date

July 5, 2011

Conditions

Stage IV Adrenocortical Carcinoma

Interventions

DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston